# Dose Ranging Study of Albiglutide in Japanese Subjects

> **NCT01098461** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 215 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **BIOLOGICAL:** albiglutide
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT01098461
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2017-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01098461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01098461, "Dose Ranging Study of Albiglutide in Japanese Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01098461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*